Source-grounded facts extracted from Orthofix Medical Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Orthofix Medical Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
“On March 6, 2023, Orthofix Medical Inc. (the “Company”) issued a news release announcing, among other things, its financial results for the fourth quarter and year ended December 31, 2022.”
Orthofix Medical Inc. reported preliminary financial results for the fiscal quarter and year ended December 31, 2022.
“On January 9, 2023, Orthofix Medical Inc. (the “Company”) issued a news release announcing, among other things, its preliminary unaudited net sales for the fiscal quarter and year ended December 31, 2022.”
Orthofix Medical Inc. completed an acquisition involving SeaSpine Holdings Corporation for 0.4163 shares of Orthofix common stock per share of SeaSpine common stock (closed 2023-01-05).
“Merger, each share of common stock of SeaSpine, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into the right to receive 0.4163 shares of common stock of Orthofix, par value $0.10 per share (the “ Orthofix common stock ”). No fractional shares of Orthofix common stock were issued in the Merger. As a result”
Orthofix Medical Inc. terminated Credit Agreement with Wells Fargo Bank, National Association (effective 2023-01-05).
“In connection with the Merger, on January 5, 2023, SeaSpine is repaying all of the outstanding obligations in respect of principal, interest and fees under the Amended and Restated Credit Agreement (the “ Credit Agreement ”), dated July 27, 2018, among SeaSpine and Project Maple Leaf Holdings ULC, as guarantors, and SeaSpine Orthopedics Corporation, SeaSpine, Inc., ISOTIS, Inc., SeaSpine Sales LLC, ISOTIS Orthobiologics, Inc., Theken Spine, LLC, SeaSpine Orthopedics Intermediate Co, Inc., 7D Surgical USA Inc. and 7D Surgical ULC, as borrowers, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent, and terminated all applicable commitments under the Credit Agreement.”
Jon C. Serbousek changed role as Executive Chairman at Orthofix Medical Inc..
“appointed Keith C. Valentine as Orthofix’s President and Chief Executive Officer (succeeding Jon C. Serbousek, who will now serve as Executive Chairman)”
Keith C. Valentine was appointed as President and Chief Executive Officer at Orthofix Medical Inc..
“appointed Keith C. Valentine as Orthofix’s President and Chief Executive Officer (succeeding Jon C. Serbousek, who will now serve as Executive Chairman)”
Orthofix Medical Inc. shareholders approved Approval of issuance of Orthofix common stock to SeaSpine stockholders in connection with the merger. at the 2023-01-04 meeting.
“Proposal 1: Orthofix Share Issuance. To approve the issuance of Orthofix common stock, par value $0.10 per share, to SeaSpine stockholders in connection with the merger, as contemplated by the Agreement and Plan of Merger, dated as of October 10, 2022, by and among Orthofix Medical Inc., Orca Merger Sub Inc. and SeaSpine Holdings Corporation. For Against Abstain 17,121,777 264,278 131,200”
Orthofix Medical Inc. reported third quarter ended September 30, 2022 results: revenue $114.0 million, net income Net loss was $(10.7) million, EPS $(0.53) per share. Guidance reaffirmed.
“Orthofix Reports Third Quarter 2022 Results • Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year • Global Orthopedics net sales growth of 19% on a constant currency basis driven by new product and channel investments • GAAP EPS of ($0.53) and adjusted EPS of $0.13”
Paul Gonsalves departed as President of Global Orthopedics at Orthofix Medical Inc..
“Mr. Gonsalves has stepped down from such position as of April 8, 2022, and also intends to resign as an employee on April 15, 2022, to pursue other opportunities.”
Kimberley A. Elting changed role as President of Global Orthopedics at Orthofix Medical Inc..
“Kimberley A. Elting, the Company’s Chief Legal and Development Officer, has succeeded Paul Gonsalves as the Company’s President of Global Orthopedics.”
Thomas A. West was appointed as director at Orthofix Medical Inc..
“Effective as of December 13, 2021, the Board of Directors (the “ Board ”) of Orthofix Medical Inc. (the “ Company ”), consistent with a recommendation made by the Board’s Nominating and Governance Committee, has appointed Thomas A. West as a director.”
Wayne C. Burris was appointed as Director at Orthofix Medical Inc..
“Effective as of September 22, 2021, the Board of Directors (the “ Board ”) of Orthofix Medical Inc. (the “ Company ”), consistent with a recommendation made by the Board’s Nominating and Governance Committee, has appointed Wayne C. Burris as a director.”
Alexis V. Lukianov resigned as Director at Orthofix Medical Inc..
“On July 3, 2021, Alexis V. Lukianov notified the Board of Directors (the “ Board ”) of Orthofix Medical Inc. (the “ Company ”) of his decision to resign from the Board effective as of July 5, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.